Investor relations

Investor relations

Our science-led strategy is key to delivering long-term value for patients, employees and shareholders.

NYSE: MRK
November 29, 2022 2:39 pm ET
Delayed at least 20 minutes

View stock information

Latest news, events & financials

November 29, 2022

Merck Announces First-Quarter 2023 Dividend

November 22, 2022

Merck Announces Phase 3 KEYNOTE-859 Trial Met Primary Endpoint of Overall Survival in Patients With HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

November 21, 2022

Merck to Present at the 5th Annual Evercore ISI HealthCONx Conference

View all

December 01, 2022

Featured

Merck & Co., Inc. at the 5th Annual Evercore ISI HealthCONx Conference

Add to Calendar Webcast

February 02, 2023

Earnings

Merck & Co., Inc. Q4 2022 Earnings Call

Add to Calendar

April 27, 2023

Earnings

Merck & Co., Inc. Q1 2023 Earnings Call

Add to Calendar

August 01, 2023

Earnings

Merck & Co., Inc. Q2 2023 Earnings Call

Add to Calendar

View all

3Q22 Merck Earnings Announcement
PDF

3Q22 Merck Other Financial Disclosures
PDF

View all

Merck & Co., Inc. at the 5th Annual Evercore ISI HealthCONx Conference

Add to Calendar

Webcast

See full agenda

Our pipeline shows our relentless pursuit of the next breakthrough.

Explore our pipeline

Phase II programs

Phase III programs

Under review

Illustration of leaders speaking on stage

Our leadership

Our deep bench of talent has the knowledge, commitment and expertise to successfully execute on our innovation strategy.

Leadership

Environmental, Social & Governance (ESG)

Supporting the future of our business and the health and well-being of patients, people and communities around the world.

Download our 2021/2022 ESG Progress Report

Download our ESG financing documents:

2021 Sustainability financing framework

Second-party opinion (SPO) on the bond framework

We're led by our science

We follow the science to our next breakthrough, leaving no stone unturned.

View our stories

Innovation

Merck’s Q2 2022 earnings report

Merck’s (NYSE: MRK) Q2 2022 results deliver robust sales growth and important clinical advancements. The company announced Q2 worldwide sales of $14.6 billion, an increase of 28% from Q2 2021. “I continue to be immensely proud of how the Merck team is performing in all facets of our business – scientifically, commercially and operationally,” said Robert […]

Next: Merck’s Q2 2022 earnings report